Barely Significant
← all excerpts

MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.

Neuro Oncol · 2020 · PMC6954444 · PMID 31504799

Europe PMCDOI
1
hedged sentence
0.0100
closest p · 0.2× alpha
0.0100
boldest claim

The sentences

a nonsignificant trendP < 0.01actually significant
Whereas mice receiving only OTSSP167 or trametinib showed a nonsignificant trend toward improved survival, only mice receiving both compounds had a significantly improved median survival (30 vs 23 days, log-rank test: P < 0.01; Fig. 6 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.